Literature DB >> 30522750

Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome: The importance of gastrointestinal related cognitions, behaviours and general anxiety.

Sula Windgassen1, Rona Moss-Morris1, Kimberley Goldsmith1, Trudie Chalder2.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterised by abdominal pain and altered bowel movements. Cognitive behavioural therapy (CBT) has been shown to be effective in reducing symptom severity in IBS and enhancing quality of life/functioning. The present study sought to identify how CBT achieves change in these outcomes.
METHOD: Secondary analysis was conducted on 149 patients with irritable bowel syndrome who had been randomised to cognitive behavioural therapy plus an antispasmodic medication or antispasmodic alone. Single and sequential mediation was modelled using structural equation modelling. Gastrointestinal (GI) related avoidance behaviour, safety behaviour, cognitions and general anxiety were included as mediators.
RESULTS: GI safety behaviours, cognitions and general anxiety mediated treatment effect on the outcomes of symptom severity and work and social adjustment. Avoidance behaviour was not a significant mediator for either outcome. Sequential mediation models indicated that unhelpful GI related cognitions reduced before anxiety did, and this sequential path (R➔GI related cognitions➔anxiety➔outcome) was significant for both symptom severity (b = -0.22, CI [-0.40 to -0.90], p = .005) and work and social adjustment (b = -0.26, CI [-0.44 to -0.11], p = .003) where 'R' is randomisation. Reduction in GI safety behaviours also preceded reduction in anxiety. This sequence (R ➔GI safety behaviours➔anxiety➔outcome) was significant for both symptom severity (b = -0.11, CI [-0.24 to -0.01], p = .049) and work and social adjustment (b = -0.12, CI [-0.23 to -0.03], p = .03).
CONCLUSION: Results suggest that it is important for psychological treatments to target IBS specific factors for change.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Cognitive behaviour therapy; Illness related cognitions; Irritable bowel syndrome; Safety behaviours; Treatment mechanisms

Mesh:

Year:  2018        PMID: 30522750     DOI: 10.1016/j.jpsychores.2018.11.013

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  5 in total

1.  A Comprehensive Self-Management Program With Diet Education Does Not Alter Microbiome Characteristics in Women With Irritable Bowel Syndrome.

Authors:  Kendra J Kamp; Anna M Plantinga; Kevin C Cain; Robert L Burr; Pamela Barney; Monica Jarrett; Ruth Ann Luna; Tor Savidge; Robert Shulman; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2021-01-08       Impact factor: 2.318

2.  Risk Factors for Self-reported Irritable Bowel Syndrome With Prior Psychiatric Disorder: The Lifelines Cohort Study.

Authors:  Francis Creed
Journal:  J Neurogastroenterol Motil       Date:  2022-07-30       Impact factor: 4.725

3.  An interpretative phenomenological analysis of the development and maintenance of gluten-related distress and unhelpful eating and lifestyle patterns in coeliac disease.

Authors:  Rose-Marie Satherley; Fiona Lerigo; Suzanne Higgs; Ruth Howard
Journal:  Br J Health Psychol       Date:  2022-02-15

4.  Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome.

Authors:  Jeffrey M Lackner; James Jaccard
Journal:  J Consult Clin Psychol       Date:  2021-05

5.  Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome.

Authors:  Kaveh Naseri; Hossein Dabiri; Mohammad Rostami-Nejad; Abbas Yadegar; Hamidreza Houri; Meysam Olfatifar; Amir Sadeghi; Saeede Saadati; Carolina Ciacci; Paola Iovino; Mohammad Reza Zali
Journal:  BMC Gastroenterol       Date:  2021-07-14       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.